Press release as PDF

Annual Report 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the Annual Report for 2013 now is available at the company’s website:

Annual Report 2013

“2013 was, without doubt, one of the most eventful years in Medivir’s 25-year history! The biggest single event during the year was the marketing approval of simeprevir – a pharmaceutical for the treatment of patients with chronic hepatitis C that we have helped develop. The approval has allowed the launch of simeprevir in Japan, Canada and the USA. Hepatitis C infected patients can now be treated using a drug that we have helped discover and develop. It is a source of great satisfaction to all Medivir employees, myself included, that we have developed a pharmaceutical all the way from a concept to a new treatment that can cure people and save lives,” said Medivir’s CEO, Maris Hartmanis, in his CEO’s Statement in this year’s Annual Report.”

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Page updated 15 maj 2017